Vectorite Biomedical Inc. (TPEX:4170)

Market Cap	682.83M
Revenue (ttm)	67.90M
Net Income (ttm)	-23.19M
Shares Out	43.77M
EPS (ttm)	-0.53
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	431,789
Average Volume	68,240
Open	15.00
Previous Close	14.85
Day's Range	15.00 - 18.15
52-Week Range	10.40 - 18.15
Beta	0.39
RSI	65.09
Earnings Date	Apr 27, 2026

About Vectorite Biomedical

Vectorite Biomedical Inc. engages in the research and development of biotechnology in Taiwan and internationally. It offers cell preparation product manufacturing; and collection, processing, and storage management of immune cells. The company’s cell preparation products are used in the field of infectious diseases and inflammation, cancer, and tumor diseases. Vectorite Biomedical Inc. was founded in 1993 and is based in New Taipei City, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1993
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4170

Financial Performance

In 2024, Vectorite Biomedical's revenue was 57.77 million, an increase of 3.43% compared to the previous year's 55.85 million. Losses were -40.05 million, 506.8% more than in 2023.